People with severe diabetes in US are cured in small trial of new drug
The experimental treatment involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. PHOTO ILLUSTRATION: PEXELS
People with severe diabetes in US are cured in small trial of new drug
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need much lower doses.
The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence.
The study was presented on June 20 at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine.
'It's trailblazing work,' said Dr Mark Anderson, professor and director of the diabetes center at the University of California, San Francisco, who was not involved in the study.
'Being free of insulin is life changing, who was not involved in the study,' he said.
Vertex, like other drug companies, declined to announce the treatment's cost before the Food and Drug Administration approves it.
A Vertex spokesperson said the company had data only on the population it studied so it could not yet say whether the drug would help others with Type 1 diabetes.
About 2 million Americans have Type 1 diabetes, which is caused when the immune system destroys islet cells. A subset of islet cells, the beta cells, secrete insulin. Without insulin, glucose cannot enter cells. Patients with Type 1 must inject carefully calibrated doses of the hormone to substitute for the insulin their body is missing.
Type 1 is different from the more common Type 2 diabetes, which usually occurs later in life.
Controlling insulin levels is a constant, often costly effort. Elevated blood sugar levels can damage the heart, kidneys, eyes and nerves. But if levels fall too low, people can feel shaky, pass out or have seizures.
The patients in the study are among the estimated 30 per cent with a complication of Type 1 diabetes – hypoglycemic unawareness. Those with the condition have no warning when their glucose levels are falling precipitously. They lack the normal signs like shakiness or sweating that can signal a need for glucose.
Patients with hypoglycemic unawareness can suddenly pass out, have seizures or even die.
It's a frightening way of life, said Dr Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study.
'You worry all day, every day where your glucose is and what you eat and when you exercise,' he added.
Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months, Dr Reichman said.
He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment.
If the study continues to show positive results, the company expects to submit an application to the FDA in 2026.
'For the short term, this looks promising' for severely affected patients like those in the study,' said Dr Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study.
But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer.
'The argument is this immunosuppression is not as dangerous as what we typically use for kidneys, hearts and lungs, but we won't know that definitely for many years,' Dr Hirsch said.
Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said.
The treatment is the culmination of work that began more than 25 years ago when a Harvard researcher, Dr Doug Melton, vowed to find a cure for Type 1 diabetes. His 6-month-old boy developed the disease and, then, so did his adolescent daughter. His passion was to find a way to help them and other patients.
He began, he said, with an 'unwavering belief that science can solve the most difficult problems'.
It took 20 years of painstaking, repetitive, frustrating work by Dr Melton and a team of about 15 people to find the right chemical cocktail to turn stem cells into islet cells. He estimated that Harvard and others spent US$50 million (S$64 million) on the research.
Dr Peter Butler, a professor of medicine at UCLA and a consultant to Vertex, said he was awed by the achievement of the Harvard team.
'The fact that it worked at all is just freaking amazing to me,' he said. 'I can guarantee there were a thousand negative experiments for every positive one.'
When Dr Melton finally succeeded, he needed a company to take the discovery into the clinic. He joined Vertex, which took up the challenge.
The first patient to get the experimental therapy, Mr Brian Shelton, got an infusion in 2021. He had been plagued by episodes of plummeting blood sugar that made him lose consciousness. Once he crashed his motorcycle into a wall, and another time he passed out in a yard while working his mail delivery route.
The infusion cured him, but he died shortly afterward from what Vertex described as dementia symptoms that began before his treatment.
Recruitment of the 12 patients in the new report proceeded slowly, Reichman said, because of the strict entry requirements. Some who qualified backed out when they heard they would have to take immunosuppressive drugs, he added.
One who joined, Ms Amanda Smith, a 36-year-old nurse in London, Ontario, said she jumped at the chance to enter the trial. Six months after the infusion, she no longer needed insulin.
'It's like a whole new life,' she said. NYTIMES
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
20 hours ago
- Straits Times
People with severe diabetes in US are cured in small trial of new drug
The experimental treatment involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. PHOTO ILLUSTRATION: PEXELS People with severe diabetes in US are cured in small trial of new drug A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need much lower doses. The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented on June 20 at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine. 'It's trailblazing work,' said Dr Mark Anderson, professor and director of the diabetes center at the University of California, San Francisco, who was not involved in the study. 'Being free of insulin is life changing, who was not involved in the study,' he said. Vertex, like other drug companies, declined to announce the treatment's cost before the Food and Drug Administration approves it. A Vertex spokesperson said the company had data only on the population it studied so it could not yet say whether the drug would help others with Type 1 diabetes. About 2 million Americans have Type 1 diabetes, which is caused when the immune system destroys islet cells. A subset of islet cells, the beta cells, secrete insulin. Without insulin, glucose cannot enter cells. Patients with Type 1 must inject carefully calibrated doses of the hormone to substitute for the insulin their body is missing. Type 1 is different from the more common Type 2 diabetes, which usually occurs later in life. Controlling insulin levels is a constant, often costly effort. Elevated blood sugar levels can damage the heart, kidneys, eyes and nerves. But if levels fall too low, people can feel shaky, pass out or have seizures. The patients in the study are among the estimated 30 per cent with a complication of Type 1 diabetes – hypoglycemic unawareness. Those with the condition have no warning when their glucose levels are falling precipitously. They lack the normal signs like shakiness or sweating that can signal a need for glucose. Patients with hypoglycemic unawareness can suddenly pass out, have seizures or even die. It's a frightening way of life, said Dr Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study. 'You worry all day, every day where your glucose is and what you eat and when you exercise,' he added. Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months, Dr Reichman said. He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment. If the study continues to show positive results, the company expects to submit an application to the FDA in 2026. 'For the short term, this looks promising' for severely affected patients like those in the study,' said Dr Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study. But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer. 'The argument is this immunosuppression is not as dangerous as what we typically use for kidneys, hearts and lungs, but we won't know that definitely for many years,' Dr Hirsch said. Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said. The treatment is the culmination of work that began more than 25 years ago when a Harvard researcher, Dr Doug Melton, vowed to find a cure for Type 1 diabetes. His 6-month-old boy developed the disease and, then, so did his adolescent daughter. His passion was to find a way to help them and other patients. He began, he said, with an 'unwavering belief that science can solve the most difficult problems'. It took 20 years of painstaking, repetitive, frustrating work by Dr Melton and a team of about 15 people to find the right chemical cocktail to turn stem cells into islet cells. He estimated that Harvard and others spent US$50 million (S$64 million) on the research. Dr Peter Butler, a professor of medicine at UCLA and a consultant to Vertex, said he was awed by the achievement of the Harvard team. 'The fact that it worked at all is just freaking amazing to me,' he said. 'I can guarantee there were a thousand negative experiments for every positive one.' When Dr Melton finally succeeded, he needed a company to take the discovery into the clinic. He joined Vertex, which took up the challenge. The first patient to get the experimental therapy, Mr Brian Shelton, got an infusion in 2021. He had been plagued by episodes of plummeting blood sugar that made him lose consciousness. Once he crashed his motorcycle into a wall, and another time he passed out in a yard while working his mail delivery route. The infusion cured him, but he died shortly afterward from what Vertex described as dementia symptoms that began before his treatment. Recruitment of the 12 patients in the new report proceeded slowly, Reichman said, because of the strict entry requirements. Some who qualified backed out when they heard they would have to take immunosuppressive drugs, he added. One who joined, Ms Amanda Smith, a 36-year-old nurse in London, Ontario, said she jumped at the chance to enter the trial. Six months after the infusion, she no longer needed insulin. 'It's like a whole new life,' she said. NYTIMES Join ST's Telegram channel and get the latest breaking news delivered to you.
Straits Times
4 days ago
- Straits Times
US to drop guidance to limit alcohol to one or two drinks per day, sources say
The updated Dietary Guidelines for Americans are expected to include a brief statement encouraging Americans to drink in moderation. PHOTO: REUTERS US to drop guidance to limit alcohol to one or two drinks per day, sources say WASHINGTON - US dietary guidelines are expected to eliminate the long-standing recommendation that adults limit alcohol consumption to one or two drinks per day, according to three sources familiar with the matter, in what could be a major win for an industry threatened by heightened scrutiny of alcohol's health effects. The updated Dietary Guidelines for Americans, which could be released as early as June, are expected to include a brief statement encouraging Americans to drink in moderation or limit alcohol intake due to associated health risks, the sources said. The guidelines are still under development and subject to change, two of the sources and a fourth individual familiar with the process said. Currently, the recommendations advise limiting drinking to one serving or less per day for women and two or less for men, widely seen as a moderate level. Similar guidelines exist in countries such as the United Kingdom, which advises limiting drinking to 14 units per week, while Canada, however, has adopted a more cautious stance, warning that health risks begin to increase after just two drinks per week. Even moderate drinking is linked to some health risks, such as higher risk of breast cancer, though some studies have also found an association with possible health benefits, such as a lower risk of stroke. The fourth source said that the scientific basis for recommending specific daily limits is limited, and the goal is to ensure the guidelines reflect only the most robust evidence. The new guidelines, developed by the US Department of Health and Human Services and the US Department of Agriculture, are closely watched internationally and influence policies ranging from school lunch programmes to medical advice. Neither department responded to requests for comment. Health Secretary Robert F. Kennedy Jr, a known teetotaler, has remained largely silent on alcohol but has emphasised a focus on whole foods in the upcoming guidelines. Some alcohol executives had feared a move towards tighter recommendations on alcohol intake as authorities like the World Health Organisation upped their warnings about alcohol's health risks. Former US Surgeon-General Vivek Murthy said alcohol consumption increases the risk of at least seven types of cancer and called for warning labels on alcoholic drinks. Major industry players, including Diageo and Anheuser-Busch InBev, have lobbied lawmakers throughout the review process. Senate records show each company spent millions on lobbying efforts related to the guidelines and a range of other issues such as tax and trade in 2024 and 2025. Both companies declined to comment. The new guidelines are set to move away from suggesting consumers limit alcohol consumption to a specific number of daily servings, according to the three sources, who asked not to be named in order to speak freely. One person said the new alcohol-related recommendation will probably be limited to a sentence or two. Another said the existing numbers tied to moderate drinking could still appear in a longer appendix. While industry representatives have lobbied lawmakers on the guidelines or how they should be decided, some officials and researchers advocated for tighter restrictions. Reports intended to inform the guidelines have meanwhile drawn different conclusions about alcohol's health effects and the science around this. 'Unhelpful' The guidelines, which are reviewed every five years, have advised drinking in moderation and defined that as no more than one drink per day for women and no more than two for men since 1990. Dr Eva Greenthal, a senior policy scientist at the Centre for Science in the Public Interest, a non-profit focused on nutrition, health and food safety, said the more general language expected in the guidelines was "so vague as to be unhelpful". Under such a change, the message that even moderate drinking can increase risks, especially for breast cancer, would get lost, she continued. Two studies were produced to inform the development of the guidelines. The first found that moderate drinking was associated with increased risk of some cancers, but a decreased risk of dying from any cause and some cardiovascular problems like stroke. The evidence for some other health impacts was insufficient to draw conclusions, it found. The other report conversely found the risk of dying from alcohol use, including increased risk for seven cancers, begins at any or low levels of alcohol use and increases with higher consumption. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
11-06-2025
- Business Times
Harvard crackdown: Can Singapore become its own intellectual leader?
THE US has long been a global science leader, with this best exemplified by its scientists creating a Covid-19 vaccine – amid a pandemic no less – within a year. Given that vaccine developments typically take a decade or more, this is nothing short of a feat, and something that has been decades in the making – a result of generous state funding for research and an openness to talent, among other factors. This is why US President Donald Trump's crusade against Harvard University and other top American institutions should give us pause, even if the fate of Ivy League colleges an ocean away may not seem, at first, to have major repercussions for Singapore. Alongside the on-and-off-again tariffs, immigration crackdown and slashing of government budgets, some observers may regard Trump's first 140 days as part of a natural ebb and flow in American politics. After all, the country has seen its fair share of upheavals in the last 249 years, having survived a civil war in the mid-19th century and, over 100 years later, lived through a particularly turbulent 1968 punctuated by two assassinations, heightened social unrest over the Vietnam War and issues related to values and race. Yet, even Americans appear spooked themselves. Experts and ordinary people, regardless of political leanings, are voicing concern that American democracy is being eroded and possibly sliding into autocracy, multiple surveys have shown. In particular, the administration's clampdown on its universities could have far-reaching consequences. America's embrace of diversity had long been part of its DNA, a trait that has drawn the world's brightest minds who, in turn, have kept its universities at the forefront of research and innovation that have resulted in life-saving drugs and key inventions. Some of these foreign talents remain in the country in pursuit of the American dream; others, equipped with new knowledge and skills, return home for the betterment of their motherland. Singapore too, has benefited from the return of US-trained scholars who have gone on to helm senior positions in government and the private sector. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up But all that is now in peril under the Trump administration, which has threatened to cut funding and foreign student quotas – actions that portend a brain drain and a possible curtailment of its research capabilities. The question is how long this crusade would last, and whether the damage wrought would be permanent. Meanwhile, foreign students and postgraduates have been targets of an immigration crackdown. Some have had their visas revoked, and others fear they would not be able to re-enter if they leave. Prospective students are naturally reconsidering their choice, given the uncertainty and apparent lack of transparency. Even researchers are hesitating to visit; a French scientist was denied entry in March because he had criticised the administration in a text message. In 2022 and 2023, Singapore sent about a quarter of its Public Service Commission scholarship recipients to the US, and many more students went at their own expense. But the latest developments raise the question whether the city-state should reconsider its reliance on the US for intellectual leadership. The imbroglio should also prompt Singapore to look afield at Europe and China, which are now seizing the opportunity to woo students and researchers seeking alternatives. A small but growing number of Singapore students have headed for European and Chinese universities over the years. And not least, Singapore might also take a leaf out of their playbook and do the same, since having a strong talent mix is what would augment its universities' standing. Rather than looking mainly to the West for intellectual leadership, Singapore has now an opportunity to build up its own for the region.
